Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry.
Journal
Targeted oncology
ISSN: 1776-260X
Titre abrégé: Target Oncol
Pays: France
ID NLM: 101270595
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
pubmed:
20
1
2019
medline:
7
1
2020
entrez:
20
1
2019
Statut:
ppublish
Résumé
Microsatellite instability (MSI) is the molecular marker for DNA mismatch repair deficiency (dMMR) in colorectal cancer (CRC) and has been associated with better survival outcomes in early stage disease. In metastatic CRC (mCRC), outcomes for patients with MSI are less clear. There is evolving evidence that treatment pathways for MSI CRC should include programmed-death 1 (PD-1) antibodies. An analysis was performed to explore the impact of MSI status on overall survival (OS) in mCRC. South Australian Metastatic CRC Registry data were analysed to assess patient characteristics and survival outcomes, comparing patients with MSI CRC with those whose tumours were microsatellite stable (MSS). Kaplan-Meier survival analysis was used to assess OS. Cox regression analysis was undertaken to assess the independence of MSI as a prognostic factor. Of 4359 patients registered on the database, 598 (14%) had been tested for, and 62 (10.1%) of these patients had, demonstrable MSI. There were significantly higher rates of right-sided primary (p < 0.001), poorly differentiated pathology (p = 0.002), and BRAF V600E mutation (p < 0.001) in the MSI group. The MSI group were also less likely to receive chemotherapy (p < 0.001) or to have liver surgery, but more likely to be diagnosed at an early stage. The median overall survival was 9.5 months for those with MSI CRC versus 21.3 months for MSS CRC patients (p = 0.052). Cox regression analysis indicated that MSI was not an independent predictor of OS. Independent predictors of better OS included having liver surgery for metastasis, having chemotherapy, and being initially diagnosed at an early stage. Only 14% of patients with mCRC were tested for MSI, and 1 in 10 were found to be MSI high. The clinical characteristics of MSI mCRC are in keeping with those previously reported. MSI in this population-based registry was associated with a numerically lower survival which did not attain statistical significance.
Sections du résumé
BACKGROUND
Microsatellite instability (MSI) is the molecular marker for DNA mismatch repair deficiency (dMMR) in colorectal cancer (CRC) and has been associated with better survival outcomes in early stage disease. In metastatic CRC (mCRC), outcomes for patients with MSI are less clear. There is evolving evidence that treatment pathways for MSI CRC should include programmed-death 1 (PD-1) antibodies.
OBJECTIVE
An analysis was performed to explore the impact of MSI status on overall survival (OS) in mCRC.
PATIENTS AND METHODS
South Australian Metastatic CRC Registry data were analysed to assess patient characteristics and survival outcomes, comparing patients with MSI CRC with those whose tumours were microsatellite stable (MSS). Kaplan-Meier survival analysis was used to assess OS. Cox regression analysis was undertaken to assess the independence of MSI as a prognostic factor.
RESULTS
Of 4359 patients registered on the database, 598 (14%) had been tested for, and 62 (10.1%) of these patients had, demonstrable MSI. There were significantly higher rates of right-sided primary (p < 0.001), poorly differentiated pathology (p = 0.002), and BRAF V600E mutation (p < 0.001) in the MSI group. The MSI group were also less likely to receive chemotherapy (p < 0.001) or to have liver surgery, but more likely to be diagnosed at an early stage. The median overall survival was 9.5 months for those with MSI CRC versus 21.3 months for MSS CRC patients (p = 0.052). Cox regression analysis indicated that MSI was not an independent predictor of OS. Independent predictors of better OS included having liver surgery for metastasis, having chemotherapy, and being initially diagnosed at an early stage.
CONCLUSIONS
Only 14% of patients with mCRC were tested for MSI, and 1 in 10 were found to be MSI high. The clinical characteristics of MSI mCRC are in keeping with those previously reported. MSI in this population-based registry was associated with a numerically lower survival which did not attain statistical significance.
Identifiants
pubmed: 30659494
doi: 10.1007/s11523-018-0615-9
pii: 10.1007/s11523-018-0615-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
85-91Commentaires et corrections
Type : CommentIn
Type : CommentIn
Références
Cancer Res. 1998 Nov 15;58(22):5248-57
pubmed: 9823339
Br J Cancer. 2016 Jun 28;115(1):25-33
pubmed: 27228287
Int Biol Biomed J. 2017 Summer;3(3):105-111
pubmed: 28825047
Br J Cancer. 2011 Mar 1;104(5):856-62
pubmed: 21285991
Oncology (Williston Park). 2007 Apr;21(5):553-64, 566; discussion 566-8, 577-8
pubmed: 17536342
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
J Clin Oncol. 2002 Feb 15;20(4):1043-8
pubmed: 11844828
Int J Mol Sci. 2017 Oct 24;18(10):
pubmed: 29064420
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759
Gastroenterology. 2015 Jan;148(1):77-87.e2
pubmed: 25280443
Nat Genet. 2006 Jul;38(7):787-93
pubmed: 16804544
Ther Adv Med Oncol. 2017 Aug;9(8):551-564
pubmed: 28794806
Clin Cancer Res. 2014 Oct 15;20(20):5322-30
pubmed: 25139339
Int J Mol Sci. 2017 Jan 06;18(1):
pubmed: 28067827
Int J Colorectal Dis. 2008 Nov;23(11):1033-9
pubmed: 18594845
J Natl Cancer Inst. 2013 Aug 7;105(15):1151-6
pubmed: 23878352
Cancer. 2011 Oct 15;117(20):4623-32
pubmed: 21456008
Ann Coloproctol. 2016 Apr;32(2):58-65
pubmed: 27218096
Anticancer Res. 2017 Jan;37(1):239-247
pubmed: 28011498
J Clin Oncol. 2018 Mar 10;36(8):773-779
pubmed: 29355075
Gut. 2017 Apr;66(4):683-691
pubmed: 26818619